383O MAYA trial: Temozolomide (TMZ) priming followed by combination with low-dose ipilimumab and nivolumab in patients with microsatellite stable (MSS), MGMT silenced metastatic colorectal cancer (mCRC)

Filippo Pietrantonio ,Michele Prisciandaro ,Alberto Zaniboni ,Massimo Milione ,Federica Marmorino ,Sabina Murgioni ,Iolanda Capone ,Sara Lonardi ,Margherita Ratti ,Celeste Cagnazzo ,Giuliana Ritorto ,Lorenzo Antonuzzo ,Maria Di Bartolomeo ,Nicoletta Pella ,Federica Palermo ,Federica Morano ,Lisa Salvatore ,Alessandra Raimondi ,Filippo Pagani ,Filippo De Braud

doi:10.1016/j.annonc.2021.08.905

383O MAYA trial: Temozolomide (TMZ) priming followed by combination with low-dose ipilimumab and nivolumab in patients with microsatellite stable (MSS), MGMT silenced metastatic colorectal cancer (mCRC)

Filippo Pietrantonio , Michele Prisciandaro + Show 18 more

Open Access

https://doi.org/10.1016/j.annonc.2021.08.905

Copy DOI

Journal: Annals of oncology : official journal of the European Society for Medical Oncology	Publication Date: Sep 1, 2021
Citations: 13	License type: publisher-specific-oa

#Mutations In Mismatch Repair Genes #Microsatellite Stable + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

The activity of TMZ in patients with mCRC is modest, but restricted to those with MSS status and MGMT silencing (negative IHC + MGMT methylation). In this hyperselected population, acquired resistance to TMZ is linked to emergence of mutations in mismatch repair genes and hypermutation. Thus, TMZ may be used as priming agent for immune-sensitization of MSS CRCs.

Full Text